Nimodipine Must Be Started Within 96 Hours of SAH Onset
You have up to 96 hours (4 days) after subarachnoid hemorrhage onset to initiate nimodipine therapy, though earlier administration is strongly preferred. 1
Critical Time Window
The FDA-approved labeling explicitly states: "Oral nimodipine therapy should commence as soon as possible within 96 hours of the onset of subarachnoid hemorrhage." 1 This represents the absolute outer limit for initiating treatment while still expecting benefit.
Why Earlier Is Better
While you technically have 96 hours, the evidence suggests starting as soon as possible after diagnosis:
The 2023 AHA/ASA guidelines emphasize that continuous administration throughout the treatment period is valuable, though "the ideal timing for when to begin nimodipine before the vasospasm window is debated." 2
Historical data from the 1980s suggested treatment should begin "between the first and sixth day after SAH, at least two days before operation and at the latest two days after the onset of secondary spasm" 3, but this predates modern understanding
The mechanism of benefit extends beyond just vasospasm prevention—nimodipine works through multiple pathways including blood-brain barrier protection, reducing microthrombosis, and preventing cortical spreading depolarization 2
Practical Implementation
Start nimodipine immediately upon diagnosis of aneurysmal SAH, not when you anticipate vasospasm. The drug requires:
- Dose: 60 mg (two 30 mg capsules) every 4 hours
- Duration: 21 consecutive days (though emerging data suggests 14 days may be adequate in select good-grade patients without DCI) 4, 5
- Route: Oral or via nasogastric tube—never intravenous 1
Common Pitfalls
Do not delay initiation waiting for aneurysm treatment or ICU admission. The 96-hour window starts from hemorrhage onset, not from aneurysm securing or ICU transfer.
Maintain consistent dosing even with mild hypotension—the guidelines note that nimodipine-induced hypotension can be managed with standard medical interventions, and interruptions in therapy correlate with increased delayed cerebral ischemia (ρ=0.431, P<0.001) 2. Only stop temporarily if significant blood pressure variability occurs.
If a patient presents beyond 96 hours, the evidence for benefit becomes uncertain, though some clinicians may still consider treatment on a case-by-case basis given the drug's established safety profile and lack of alternative proven therapies.